RxDoctor Payments Data

Alexander Calenda, MD

Urology · Warwick, RINPI 1801831607

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.1% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Pfizer at 28.8% of the total. Reporting peaked in 2023 at $1,225 and has fallen 76.1% since, to $293 in 2025.

$4,038in general payments, 2019–2025

Across 186 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$892
  • Sumitomo Pharma America, Inc.$248
  • Teleflex LLC$222
  • AbbVie$76
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$3,67891%
  • Education$3619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,038 in reported general payments places this provider in the 65th percentile of 55 urology providers in Rhode Island.

See all urology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$148,807
Medicare patients
417
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$147,567
GemtesaVibegron60$45,465
OrgovyxRelugolix14$38,273
MyrbetriqMirabegron39$28,566
Tamsulosin Hcl531$7,616
Bicalutamide131$4,239
Solifenacin Succinate34$2,751
Finasteride148$2,228
Dutasteride33$733
Alfuzosin Hcl ErAlfuzosin Hcl31$671
Allopurinol31$369
Terazosin Hcl30$356
Oxybutynin Chloride ErOxybutynin Chloride18$317
Cefadroxil88$248
Ciprofloxacin Hcl49$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$892$176,13350 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$248$83,73874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 urology providers in Rhode Island.

Other urology in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →